Show simple item record

dc.contributor.authorJubber, Ameen
dc.contributor.authorMoorthy, Arumugam
dc.date.accessioned2022-12-12T13:56:41Z
dc.date.available2022-12-12T13:56:41Z
dc.date.issued2022-08
dc.identifier.citationJubber, A., Woodward, J., Tahir, H., & Moorthy, A. (2022). Venous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect?. Expert opinion on drug safety, 21(8), 1005–1007.en_US
dc.identifier.other10.1080/14740338.2022.2100343
dc.identifier.urihttp://hdl.handle.net/20.500.12904/16053
dc.description.urihttps://www.tandfonline.com/doi/full/10.1080/14740338.2022.2100343en_US
dc.language.isoenen_US
dc.subjectVenous thromboembolismen_US
dc.subjectInflammatory arthritisen_US
dc.subjectJanus kinase (JAK) inhibitorsen_US
dc.titleVenous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect?en_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttps://doi.org/10.1080/14740338.2022.2100343en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2022-07-13
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record